Overview

Determinants of Mercaptopurine Toxicity in Paediatric Acute Lymphoblastic Leukemia Maintenance Therapy

Status:
Enrolling by invitation

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

The present study was conducted to assess the population pharmacokinetics of 6-mercaptopurine (6-MP) in Pediatric Acute Lymphoblastic Leukemia (ALL) and genetic polymorphisms

Phase:

Phase 4

Details

Lead Sponsor:

Shandong University

Treatments:

Mercaptopurine